Displaying drugs 1576 - 1600 of 2635 in total
ANC-501
ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment of Adults With Major Depressive Disorder).
Investigational
Ciliary neurotrophic factor
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
Investigational
ATYR-1940
Investigational
NDI-5001
Investigational
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
BHV-5000
BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is lanicemine.
Investigational
GI-5005
GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as...
Investigational
ADH-503
Investigational
RAD 502
Investigational
CX501
Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by Cellerix and is in phase I of clinical trials.
Investigational
UK-500001
UK-500,001 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
NVP-LEQ-506
LEQ506 has been used in trials studying the treatment of Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, and Locally Advanced or Metastatic Basal Cell Carcinoma.
Investigational
RO-5045337
RO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).
Investigational
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
AZD-5069
Investigational
SUVN-502
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
Investigational
Racivir
Racivir, also known as RCV, is an oxothiolane nucleoside reverse transcriptase inhibitor similar to emtricitabine and lamivudine. Racivir is a 50:50 mixture of emtricitabine and its positive enantiomer. Racivir has been used in trials studying the prevention of HIV Infections.
Investigational
Matched Description: … Racivir is a 50:50 mixture of [emtricitabine] and its positive enantiomer. …
IR501
IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III clinical trials.
Investigational
AT-GTX-502
AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.
Investigational
Nebicapone
Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).
Investigational
Matched Description: … 512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 ... mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg). …
Laruparetigene zovaparvovec
Investigational
UCB7362
UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essential for parasite egress and invasion. UCB7362 is estimated to achieve a significant reduction in asexual blood-stage...
Investigational
Matched Description: … dehydrogenase growth inhibition assay IC50 = 10 nM), and _in vivo_ (50 mg/kg dose in mice ... It has shown high potency in biochemical (IC50 = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate …
SLN500
SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA
Investigational
Etofenamate
Etofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID).
Experimental
Matched Mixtures name: … THER-MERAM KREM ,50 G ... THERMO ETOX 50 G KREM ... THERMOFLEX %10 + %1 KREM, 50 G …
Matched Products: … SOLUCION AL 50% / 2ML ... ETOVER 100 MG / ML SPREY, 50 ML ... DOLINE %10 SPREY, ÇÖZELTİ 50 ML …
Matched Products: … SOLUCION AL 50% / 2ML ... ETOVER 100 MG / ML SPREY, 50 ML ... DOLINE %10 SPREY, ÇÖZELTİ 50 ML …
Displaying drugs 1576 - 1600 of 2635 in total